Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) reported third-quarter 2025 results and a business update on November 12, 2025. Q3 revenue was $0.753M (including $0.703M from Symvess sales) and nine-month revenue was $1.571M. The company reported Q3 net loss of $17.5M and $19.8M cash at September 30, 2025, with ~$56.5M of net proceeds raised after quarter-end. Symvess commercial launch showed a sales ramp (from $0.1M in Q2 to $0.703M in Q3) with 25 VAC approvals covering 92 hospitals and 16 hospitals ordered product. Clinical and regulatory progress includes positive V007 two-year dialysis data, 109 patients enrolled in V012, planned supplemental BLA submission in H2 2026, and an IND submitted for a CABG first-in-human study in 2026. A new U.S. patent for a bioengineered esophagus was granted, extending IP protection into 2041.
Humacyte (NASDAQ: HUMA) presented positive two-year V007 Phase 3 results for its acellular tissue engineered vessel (ATEV) for hemodialysis arteriovenous access at ASN Kidney Week 2025.
In 242 randomized US patients followed to 24 months, the ATEV showed superior average duration of access use in female patients (15.8 vs 10.0 months, p<0.0137) and in the target high‑risk group of females plus males with obesity and diabetes (14.8 vs 9.1 months, p=0.0114). For all patients, duration was 13.3 vs 12.3 months (p=0.7446). Prior co‑primary endpoints at 6 and 12 months also favored ATEV. Safety was comparable to AV fistula, with low infection rates; ATEV had more thrombosis and stenosis events but most were successfully treated. ATEV remains investigational outside approved trauma use.
Humacyte (Nasdaq: HUMA) will release third quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 AM Eastern Time to provide a corporate and financial update. The webcast will be accessible 15 minutes prior to the start time and a replay will be available on the company's investor website for at least 30 days.
Dial-in numbers are provided for U.S. and international investors and a conference ID is listed for access. The event covers the company’s corporate and financial update and is scheduled to coincide with the quarterly results release.
Humacyte (Nasdaq: HUMA) announced publication (Oct 30, 2025) of a study in AAST Trauma Surgery & Acute Care Open comparing Symvess to autologous vein for extremity arterial trauma.
Using matched data from Humacyte trials (V005, V017) and the PROOVIT registry, Symvess showed similar short-term outcomes for patency, limb salvage, infection, and mortality: primary patency 86.6% vs 91.8%, secondary patency 91.0% vs 97.7%, amputation 7.5% vs 8.2%, conduit infection 1.5% vs 0%, and death 4.5% vs 4.5%.
Symvess is indicated as an off-the-shelf conduit when autologous vein is not feasible; safety warnings include graft rupture, anastomotic failure, thrombosis, and requirement for antiplatelet therapy.
Humacyte (Nasdaq: HUMA) priced an oversubscribed registered direct offering to raise approximately $60.0 million of gross proceeds by selling 28,436,018 shares of common stock together with warrants to purchase 28,436,018 shares.
The combined purchase price per share and accompanying warrant is $2.11. Warrants become exercisable 180 days after issuance, have an exercise price of $2.11, and expire on April 7, 2031. The offering is expected to close on or about October 8, 2025, subject to customary closing conditions. D. Boral Capital is acting as exclusive placement agent. The offering is being made under a Form S-3 shelf registration declared effective September 22, 2025.
Humacyte (Nasdaq: HUMA) announced publication of long-term real-world results for Symvess treating wartime extremity vascular trauma in Ukraine, published Oct 6, 2025 in Military Medicine. In 17 patients followed up to 18 months the study reported 87.1% patency, 100% limb salvage, and zero infections, amputations, or deaths. The 30-day primary and secondary patency was 93.8%. No immunologic rejection was observed. Symvess is indicated as an off-the-shelf acellular tissue engineered vessel for adult extremity arterial injury when autologous vein is not feasible. Important safety information includes a Boxed Warning for graft failure, risk of thrombosis, anastomotic failure within 36 days in trials, and potential transmissible-agent risk despite negative test results.
Humacyte (Nasdaq: HUMA) has secured a new U.S. patent for its bioengineered esophagus, expanding its intellectual property portfolio. The patent, titled "Tubular Prostheses (Esophagus)," provides protection until 2041 and covers key structural and mechanical attributes for esophageal replacement.
The company has now secured patent coverage for bioengineered trachea, esophagus, and urinary conduits across multiple regions including the United States, Europe, Canada, and Australia. These advanced tissue constructs have been evaluated in early preclinical models, with plans for future testing in large animal models.
The technology is part of Humacyte's broader pipeline, which includes ATEV™, CTEV, and BioVascular Pancreas™ (BVP™), all utilizing the same bioengineering platform as their Symvess™ product. The company plans to seek corporate partnerships to accelerate development.
Humacyte (Nasdaq: HUMA) has published promising preclinical data in JACC: Basic to Translational Science regarding their coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, conducted on five adult baboons, demonstrated that all CTEVs remained patent throughout the 6-month study period.
Key findings show the CTEV successfully recellularized with host cells and adapted to match native artery size. The company plans to advance to first-in-human trials, with an IND application to the FDA expected in Q4 2025. This innovation could potentially address the limitations of current saphenous vein grafts, which show approximately 50% failure rate at 10 years.
Humacyte (Nasdaq: HUMA) announced the publication of clinical outcomes in the Journal of Vascular Surgery for patients treated with Symvess™, their FDA-approved bioengineered human tissue vascular conduit. The study focused on 12 patients with hospital-acquired vascular complications from their V005 pivotal Phase 2/3 clinical trial.
Key results showed 92% secondary patency (blood flow) at an average follow-up of 23.3 months, with 100% limb salvage and zero conduit infections. The patients required arterial repair due to various complications including vascular interventions, tumor resections, and orthopedic surgery injuries. Symvess received full FDA approval in December 2024 for use in adults requiring urgent revascularization for extremity arterial injury.
Humacyte (Nasdaq: HUMA) reported Q2 2025 financial results and business updates. The company generated $301,000 in revenue for Q2 2025 and $818,000 for H1 2025. Key highlights include 82 civilian hospitals now approved to purchase Symvess™, and ECAT approval making the product available to 35 Military Treatment Facilities and 160 VA hospitals.
The company implemented cost reduction measures, including a 30-employee workforce reduction, expecting to save approximately $50 million through 2026. Q2 resulted in a net loss of $37.7 million, with cash position of $88.4 million as of June 30, 2025. July product sales of $0.3 million exceeded total H1 sales, showing commercial momentum.
Clinical progress includes positive V007 Phase 3 trial results for dialysis access, particularly strong in high-risk subgroups, and achievement of 100-patient enrollment in the V012 Phase 3 trial.